Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer

THURSDAY, May 11, 2023 -- Cabozantinib plus nivolumab and ipilimumab yields significantly longer progression-free survival than treatment with cabozantinib plus nivolumab alone among patients with previously untreated, advanced renal-cell carcinoma...